Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...
Hosted on MSN

Dexcom maps G8 launch, coverage expansion and double-digit growth at investor day

DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and ...
Insurancenewsnet.com

Dexcom Wins Access to Dexcom One for 100,000 People Living With Type 2 Diabetes

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating ...